Flexion Therapeutics has presented new data from a Phase IIb dose-ranging trial of its lead compound, FX006, at the 2013 American College of Rheumatology Annual Scientific Meeting in San Diego, CA. The company reported that patients with osteoarthritis (OA) of the knee receiving a single injection of  FX006 in the 12-week clinical trial experienced enhanced pain relief relative to those patients receiving the currently available, approved injectable suspension of TCA (TCA suspension) over 12 we...